Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 20/20 | 0.86 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.67 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.67 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.67 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20580638 | 1.00 | BCL2 (0.86) | BCL2BCL2L1MCL1TMEM97BCL2L2 | |
| SCHEMBL26347879 | 0.92 | BCL2 (0.82) | BCL2BCL2L1MCL1BCL2L2 | |
| SCHEMBL19839951 | 0.92 | BCL2 (0.82) | BCL2 | |
| SCHEMBL29376388 | 0.92 | BCL2 (0.82) | BCL2 | |
| SCHEMBL22858621 | 0.92 | BCL2 (0.85) | BCL2 | |
| SCHEMBL20580477 | 0.92 | BCL2 (0.86) | BCL2 | |
| SCHEMBL20580429 | 0.92 | BCL2 (0.86) | BCL2 | |
| SCHEMBL29651986 | 0.92 | BCL2 (0.86) | BCL2 | |
| SCHEMBL29651993 | 0.92 | BCL2 (0.86) | BCL2 | |
| SCHEMBL20580603 | 0.91 | BCL2 (0.82) | BCL2BCL2L1MCL1BCL2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053815-A1 | COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2026-02-26 | — | — | US | disclosed |
| US-12370197-B2 | Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-07-29 | — | — | US | disclosed |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230301989-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-11718613-B2 | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-08-08 | — | — | US | disclosed |
| US-20220143039-A1 | COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301989-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | SSB, BCL3, BCL6 | BCL2 8/4885BCL2L1 7/4885MCL1 75/4885 |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | FABP1, LIPC, PNLIP | BCL2 43/4885BCL2L1 39/4885MCL1 1338/4885 |
| US-20220143039-A1 | COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | BCL2, BCL3, BCL2L13 | BCL2 1/4885BCL2L1 6/4885MCL1 13/4885 |
| US-12370197-B2 | Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases | BCL2, BCL3, BCL2L13 | BCL2 1/4885BCL2L1 6/4885MCL1 13/4885 |
| US-11718613-B2 | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors | BCL2A1, BCL3, BCL2 | BCL2 3/4885BCL2L1 6/4885MCL1 18/4885 |
| US-20260053815-A1 | COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | BCL3, BCL2, BCL2L1 | BCL2 2/4885BCL2L1 3/4885MCL1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.